Nelarabine is named as an intervention in 2 current clinical trials in our Canada and Australia registers. None are recruiting at the moment. The most common phase is Phase 3. The sponsor with the most trials is Dana-Farber Cancer Institute (1). The most-studied condition is Acute Lymphoblastic Leukemia, Pediatric. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Of the three regulators tracked here, the first to approve Nelarabine was the US, on 28 Oct 2005. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
| Study | Phase | Status | Lead sponsor | Registers |
|---|
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Nelarabine. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Test-Retest Evaluation of [18F]F-AraG in Lung Tumors (TREAT)
2025-522404-24-01 · CTIS ↗ · Neoplasms
|
Phase 3 | Authorised | Amsterdam UMC Stichting | Netherlands |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Nelarabine on the HPRA medicines list.
No entry for Nelarabine in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Dana-Farber Cancer Institute | 1 |
| St. Jude Children's Research Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in Australia | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our Canada and Australia registers name Nelarabine (also registered as Compound 506U78) as a drug or biological intervention, as of the registry sync on 6 October 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Dana-Farber Cancer Institute (1) and St. Jude Children's Research Hospital (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Nelarabine, for example ATRIANCE 5mg/ml Solution for Infusion (Sandoz Pharmaceuticals d.d.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Nelarabine has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nelarabine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nelarabine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nelarabine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 6 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
